Evaluation of the effectiveness of caspofungin against febrile neutropenia and the factors related to the alteration in its plasma concentration
| Autor: | Hisashi Tsurumi, Kiyoyuki Kitaichi, Yuri Miyahara, Minami Fujimura, Yuhei Shibata, Katsura Tsukamoto, Midori Soda, Akio Suzuki, Takeshi Hara, Yuna Sadaka, Mika Yasue, Miho Yamamoto, Hiroko Kato |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Adult Male medicine.medical_specialty Antifungal Agents Echinocandin 030106 microbiology Kidney Gastroenterology 03 medical and health sciences chemistry.chemical_compound Young Adult 0302 clinical medicine Sex Factors Pharmacokinetics Japan Liver Function Tests Caspofungin Internal medicine medicine Humans Pharmacology (medical) 030212 general & internal medicine Dosing Infusions Intravenous Aged Febrile Neutropenia business.industry Body Weight Common Terminology Criteria for Adverse Events Middle Aged medicine.disease Infectious Diseases Treatment Outcome chemistry Tolerability Liver Toxicity Female Chemical and Drug Induced Liver Injury business Febrile neutropenia medicine.drug |
| Zdroj: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 25(10) |
| ISSN: | 1437-7780 |
| Popis: | Caspofungin (CPFG) is an echinocandin antifungal agent that inhibits the synthesis of β-1, 3-D-glucan, a critical component of the cell wall of target fungi. Several clinical studies have confirmed the efficacy and safety of CPFG in patients with febrile neutropenia (FN); however, there are no reports available in Japanese patients with FN. Therefore, we investigated the therapeutic efficacy and pharmacokinetics of CPFG as an empirical therapy in a Japanese hospital. Twenty-four Japanese patients, who were diagnosed with FN at Gifu University Hospital from February 2014 to August 2017, were enrolled. Blood samples were collected at the end of CPFG dosing (0.5 h after the infusion) on day 1 and immediately prior to the next infusion on days 2, 3, and 4. The concentration of CPFG in plasma was measured by high-performance liquid chromatography. The efficacy was assessed by five of the component endpoints, and safety was monitored according to the Common Terminology Criteria for Adverse Events. CPFG showed an excellent effect against FN (75%, 18/24), without any serious hepatic or renal toxicity. Regarding the pharmacokinetics, the plasma concentration of CPFG was significantly correlated with body weight; although, no correlation was observed between the plasma concentration of CPFG and the other factors investigated, such as gender or laboratory results. These results suggest the high efficacy, safety, and tolerability of CPFG as an empirical antifungal therapy for Japanese patients with FN. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect